Inmune Bio (INMB) Payables (2017 - 2025)
Inmune Bio (INMB) has disclosed Payables for 9 consecutive years, with $7.8 million as the latest value for Q4 2025.
- Quarterly Payables rose 18.79% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 18.79% year-over-year, with the annual reading at $7.8 million for FY2025, 18.79% up from the prior year.
- Payables hit $7.8 million in Q4 2025 for Inmune Bio, up from $6.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $10.6 million in Q3 2024 to a low of $8000.0 in Q3 2022.
- Historically, Payables has averaged $4.1 million across 5 years, with a median of $3.0 million in 2023.
- Biggest five-year swings in Payables: surged 46122.08% in 2021 and later plummeted 99.81% in 2022.
- Year by year, Payables stood at $80000.0 in 2021, then surged by 6407.5% to $5.2 million in 2022, then surged by 51.77% to $7.9 million in 2023, then fell by 17.24% to $6.5 million in 2024, then grew by 18.79% to $7.8 million in 2025.
- Business Quant data shows Payables for INMB at $7.8 million in Q4 2025, $6.9 million in Q3 2025, and $25000.0 in Q2 2025.